Johnson & Johnson's nipocalimab receives FDA Fast Track status for Sjögren's disease, following strong Phase 2 trial results ...

The FDA has granted fast-track designation to nipocalimab for the treatment of Sjögren’s disease, according to a press ...

Johnson & Johnson (NYSE:JNJ) said on Tuesday that it received U.S. FDA's Fast Track designation for nipocalimab to treat adult patients with moderate-to-severe Sjögren's disease. In November last year ...

Johnson & Johnson announced that the U.S. FDA has granted investigational nipocalimab Fast Track designation for the treatment of adult ...

FDA grants Fast Track designation to Johnson & Johnson’s investigational therapy nipocalimab for the treatment of moderate-to-severe Sjögren’s disease, which could be the first targeted therapy ever ...

OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the ...

The use of CLPH-511 in acute hemorrhage is currently being investigated in a Phase 2/3 adaptive design study, titled “Randomized Controlled Trial Comparing Dimethyl Sulfoxide Cryopreserved Platelets ...

Bexobrutideg, a first-in-class Bruton’s tyrosine kinase degrader, has been granted orphan drug designation from the FDA in ...

Pharmaceutical consultants apply their comprehensive expertise in different areas to accelerate the drug development process.

The FDA granted fast track designation to ATSN-201 for the treatment of X-linked retinoschisis, according to a press release ...

“Fast track was first introduced by FDA to expedite development and review of drugs to treat serious conditions lacking any FDA-approved drug,” commented Gary S. Jacob, Ph.D., Chief Executive ...

Urcosmid is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor, typically found on immune ...